

# Julian Segura

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9420802/publications.pdf>

Version: 2024-02-01

186  
papers

12,733  
citations

81900

39  
h-index

25787

108  
g-index

213  
all docs

213  
docs citations

213  
times ranked

14155  
citing authors

#	ARTICLE	IF	CITATIONS
1	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018, 39, 3021-3104.	2.2	6,826
2	Clinical Features of 8295 Patients With Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring. <i>Hypertension</i> , 2011, 57, 898-902.	2.7	696
3	Relationship between Clinic and Ambulatory Blood-Pressure Measurements and Mortality. <i>New England Journal of Medicine</i> , 2018, 378, 1509-1520.	27.0	420
4	Prevalence and Factors Associated With Circadian Blood Pressure Patterns in Hypertensive Patients. <i>Hypertension</i> , 2009, 53, 466-472.	2.7	312
5	High prevalence of masked uncontrolled hypertension in people with treated hypertension. <i>European Heart Journal</i> , 2014, 35, 3304-3312.	2.2	186
6	Blood Pressure Control and Physician Management of Hypertension in Hospital Hypertension Units in Spain. <i>Hypertension</i> , 2004, 43, 1338-1344.	2.7	183
7	Effectiveness of Blood Pressure Control Outside the Medical Setting. <i>Hypertension</i> , 2007, 49, 62-68.	2.7	173
8	ESC Council on hypertension position document on the management of hypertensive emergencies. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 37-46.	3.0	155
9	Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs. <i>Journal of Hypertension</i> , 2012, 30, 1211-1216.	0.5	122
10	Nocturnal Hypertension or Nondipping: Which Is Better Associated With the Cardiovascular Risk Profile?. <i>American Journal of Hypertension</i> , 2014, 27, 680-687.	2.0	106
11	Ambulatory blood pressure monitoring in hypertensive patients with high cardiovascular risk: a cross-sectional analysis of a 20 000-patient database in Spain. <i>Journal of Hypertension</i> , 2007, 25, 977-984.	0.5	102
12	Development Of Chronic Kidney Disease and Cardiovascular Prognosis in Essential Hypertensive Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 1616-1622.	6.1	100
13	Ambulatory blood pressure monitoring and development of cardiovascular events in high-risk patients included in the Spanish ABPM registry. <i>Journal of Hypertension</i> , 2012, 30, 713-719.	0.5	97
14	Ethnic Differences in the Degree of Morning Blood Pressure Surge and in Its Determinants Between Japanese and European Hypertensive Subjects. <i>Hypertension</i> , 2015, 66, 750-756.	2.7	96
15	From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency. <i>Journal of Human Hypertension</i> , 2016, 30, 463-466.	2.2	89
16	Differences Between Office and 24-Hour Blood Pressure Control in Hypertensive Patients With CKD: A 5,693-Patient Cross-sectional Analysis From Spain. <i>American Journal of Kidney Diseases</i> , 2013, 62, 285-294.	1.9	88
17	Obesity, essential hypertension and renin-angiotensin system. <i>Public Health Nutrition</i> , 2007, 10, 1151-1155.	2.2	78
18	A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. <i>Journal of Hypertension</i> , 2001, 19, 1871-1876.	0.5	76

#	ARTICLE	IF	CITATIONS
19	Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy <sup>11</sup> See Editorial by Cattran, p. 349.. <i>Kidney International</i> , 2002, 61, 219-227.	5.2	76
20	Long-term renal survival in malignant hypertension. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3266-3272.	0.7	75
21	Long-Term Renoprotective Effects of Standard Versus High Doses of Telmisartan in Hypertensive Nondiabetic Nephropathies. <i>American Journal of Kidney Diseases</i> , 2005, 46, 1074-1079.	1.9	69
22	Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. <i>Journal of Hypertension</i> , 2007, 25, 1473-1479.	0.5	68
23	Blood pressure variability increases with advancing chronic kidney disease stage. <i>Journal of Hypertension</i> , 2018, 36, 1076-1085.	0.5	63
24	Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 527-547.	1.8	62
25	Reproducibility of the circadian blood pressure pattern in 24-h versus 48-h recordings: the Spanish Ambulatory Blood Pressure Monitoring Registry. <i>Journal of Hypertension</i> , 2007, 25, 2406-2412.	0.5	56
26	Prevalence and Clinical Characteristics of Refractory Hypertension. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	54
27	Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 605-621.	1.8	51
28	Role of matrix metalloproteinase-9 in chronic kidney disease: a new biomarker of resistant albuminuria. <i>Clinical Science</i> , 2016, 130, 525-538.	4.3	48
29	Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003, 4, 43-47.	1.7	47
30	Clinical characteristics of isolated clinic hypertension. <i>Journal of Hypertension</i> , 2008, 26, 438-445.	0.5	47
31	Abnormalities in ambulatory blood pressure monitoring in hypertensive patients with diabetes. <i>Hypertension Research</i> , 2011, 34, 1185-1189.	2.7	45
32	Diurnal blood pressure variation, risk categories and antihypertensive treatment. <i>Hypertension Research</i> , 2010, 33, 767-771.	2.7	44
33	Discrepancies between Office and Ambulatory Blood Pressure: Clinical Implications. <i>American Journal of Medicine</i> , 2009, 122, 1136-1141.	1.5	43
34	Development of albuminuria and enhancement of oxidative stress during chronic renin-angiotensin system suppression. <i>Journal of Hypertension</i> , 2014, 32, 2082-2091.	0.5	43
35	Prevalence and clinical characteristics of white-coat hypertension based on different definition criteria in untreated and treated patients. <i>Journal of Hypertension</i> , 2017, 35, 2388-2394.	0.5	43
36	Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. <i>Kidney International</i> , 2004, 66, S45-S49.	5.2	42

#	ARTICLE	IF	CITATIONS
37	ACE Inhibitors and Appearance of Renal Events in Hypertensive Nephrosclerosis. <i>Hypertension</i> , 2001, 38, 645-649.	2.7	41
38	How Relevant and Frequent Is the Presence of Mild Renal Insufficiency in Essential Hypertension?. <i>Journal of Clinical Hypertension</i> , 2002, 4, 332-336.	2.0	39
39	Microalbuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression. <i>Journal of Hypertension</i> , 2012, 30, 204-209.	0.5	39
40	Short-Term and Long-Term Reproducibility of Hypertension Phenotypes Obtained by Office and Ambulatory Blood Pressure Measurements. <i>Journal of Clinical Hypertension</i> , 2016, 18, 927-933.	2.0	38
41	Citric Acid Metabolism in Resistant Hypertension. <i>Hypertension</i> , 2017, 70, 1049-1056.	2.7	36
42	Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: A review of the clinical trial evidence. <i>Clinical Therapeutics</i> , 2003, 25, 3044-3064.	2.5	35
43	Ambulatory blood pressure monitoring in daily clinical practice - the Spanish ABPM Registry experience. <i>European Journal of Clinical Investigation</i> , 2016, 46, 92-98.	3.4	35
44	Spanish Society of Nephrology document on KDIGO guidelines for the assessment and treatment of chronic kidney disease. <i>Nefrología</i> , 2014, 34, 302-16.	0.4	35
45	Hypertensive Renal Damage in Metabolic Syndrome Is Associated with Glucose Metabolism Disturbances. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 37S-42.	6.1	34
46	Magnitude of Hypotension Based on Office and Ambulatory Blood Pressure Monitoring: Results From a Cohort of 5066 Treated Hypertensive Patients Aged 80 Years and Older. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 452.e1-452.e6.	2.5	33
47	Prevalence of Masked Hypertension in Untreated and Treated Patients With Office Blood Pressure Below 130/80 mmHg. <i>Circulation</i> , 2018, 137, 2651-2653.	1.6	33
48	Urinary exosomes reveal protein signatures in hypertensive patients with albuminuria. <i>Oncotarget</i> , 2017, 8, 44217-44231.	1.8	33
49	Gender Differences in Office and Ambulatory Control of Hypertension. <i>American Journal of Medicine</i> , 2008, 121, 1078-1084.	1.5	31
50	Clinic Versus Daytime Ambulatory Blood Pressure Difference in Hypertensive Patients. <i>Hypertension</i> , 2017, 69, 211-219.	2.7	30
51	Hypotension based on office and ambulatory monitoring blood pressure. Prevalence and clinical profile among a cohort of 70,997 treated hypertensives. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 714-723.	2.3	29
52	Hypertensive patients exhibit an altered metabolism. A specific metabolite signature in urine is able to predict albuminuria progression. <i>Translational Research</i> , 2016, 178, 25-37.e7.	5.0	28
53	Psychological Factors Associated with Poor Hypertension Control: Differences in Personality and Stress between Patients with Controlled and Uncontrolled Hypertension. <i>Psychological Reports</i> , 2010, 107, 923-938.	1.7	27
54	Guidelines Updates in the Treatment of Obesity or Metabolic Syndrome and Hypertension. <i>Current Hypertension Reports</i> , 2013, 15, 196-203.	3.5	27

#	ARTICLE	IF	CITATIONS
55	Hyperuricemia, low urine urate excretion and target organ damage in arterial hypertension. <i>Blood Pressure</i> , 2003, 12, 277-283.	1.5	26
56	Calcium Channel Blockers and Renal Protection: Insights from the Latest Clinical Trials. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, S64-S66.	6.1	26
57	An update of the blockade of the renin angiotensin aldosterone system in clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2283-2292.	1.8	26
58	Association Between High and Very High Albuminuria and Nighttime Blood Pressure: Influence of Diabetes and Chronic Kidney Disease. <i>Diabetes Care</i> , 2016, 39, 1729-1737.	8.6	26
59	Hypertension in Moderate-to-Severe Nondiabetic CKD Patients. <i>Advances in Chronic Kidney Disease</i> , 2011, 18, 23-27.	1.4	24
60	Urinary alpha-1 antitrypsin and CD59 glycoprotein predict albuminuria development in hypertensive patients under chronic renin-angiotensin system suppression. <i>Cardiovascular Diabetology</i> , 2016, 15, 8.	6.8	24
61	Proteinuria: An underappreciated risk factor in cardiovascular disease. <i>Current Cardiology Reports</i> , 2002, 4, 458-462.	2.9	23
62	Dual neurohormonal intervention in CV disease: angiotensin receptor and Nephprilysin inhibition. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 915-925.	4.1	23
63	Ambulatory blood pressure in hypertensive patients with inclusion criteria for the SPRINT trial. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 947-953.e5.	2.3	22
64	On the importance of estimating renal function for cardiovascular risk assessment. <i>Journal of Hypertension</i> , 2004, 22, 1635-1639.	0.5	21
65	Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome. <i>Journal of Hypertension</i> , 2007, 25, 1711-1718.	0.5	21
66	Validation of a therapeutic scheme for the treatment of resistant hypertension. <i>Journal of the American Society of Hypertension</i> , 2011, 5, 498-504.	2.3	21
67	Factors Influencing the Systolic Blood Pressure Response to Drug Therapy. <i>Journal of Clinical Hypertension</i> , 2002, 4, 35-40.	2.0	20
68	Treatment of Prehypertension in Diabetes and Metabolic Syndrome. <i>Diabetes Care</i> , 2009, 32, S284-S289.	8.6	20
69	Kalirin and CHD7: novel endothelial dysfunction indicators in circulating extracellular vesicles from hypertensive patients with albuminuria. <i>Oncotarget</i> , 2017, 8, 15553-15562.	1.8	20
70	Manejo de la hipertensi3n resistente en una unidad multidisciplinaria de denervaci3n renal: protocolo y resultados. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 364-370.	1.2	19
71	How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: According to blood pressure or proteinuria?. <i>Current Hypertension Reports</i> , 2003, 5, 426-429.	3.5	18
72	Association between urinary albumin excretion and both central and peripheral blood pressure in subjects with insulin resistance. <i>Journal of Hypertension</i> , 2013, 31, 103-108.	0.5	18

#	ARTICLE	IF	CITATIONS
73	Prediction of development and maintenance of high albuminuria during chronic renin-angiotensin suppression by plasma proteomics. <i>International Journal of Cardiology</i> , 2015, 196, 170-177.	1.7	18
74	Plasma Molecular Signatures in Hypertensive Patients With Renin-Angiotensin System Suppression. <i>Hypertension</i> , 2016, 68, 157-166.	2.7	18
75	Resistant hypertension: new insights and therapeutic perspectives. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 188-193.	3.0	18
76	Chronic Kidney Disease as a Situation of High Added Risk in Hypertensive Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, S136-S140.	6.1	17
77	High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study. <i>International Journal of Clinical Practice</i> , 2008, 62, 723-728.	1.7	17
78	Influence of Hepatitis C Virus Infection on FK 506 Blood Levels in Renal Transplant Patients. <i>Transplantation Proceedings</i> , 1998, 30, 1264-1265.	0.6	16
79	Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes. <i>Journal of Hypertension</i> , 2004, 22, 217-222.	0.5	15
80	Microalbuminuria and cardiorenal risk: old and new evidence in different populations. <i>F1000Research</i> , 2019, 8, 1659.	1.6	15
81	Doxazosin GITS versus hydrochlorothiazide as add-on therapy in patients with uncontrolled hypertension. <i>Blood Pressure</i> , 2003, 12, 16-21.	1.5	14
82	Microalbuminuria. <i>Clinical and Experimental Hypertension</i> , 2004, 26, 701-707.	1.3	14
83	Control of hypertension in coronary heart disease. <i>International Journal of Cardiology</i> , 2009, 134, 245-247.	1.7	14
84	Rapid, Automated, and Specific Immunoassay to Directly Measure Matrix Metalloproteinase-9-Tissue Inhibitor of Metalloproteinase-1 Interactions in Human Plasma Using AlphaLISA Technology: A New Alternative to Classical ELISA. <i>Frontiers in Immunology</i> , 2017, 8, 853.	4.8	14
85	Dual-Acting Angiotensin Receptor-Nepilysin Inhibition. <i>Current Hypertension Reports</i> , 2011, 13, 74-78.	3.5	13
86	Immune system deregulation in hypertensive patients chronically RAS suppressed developing albuminuria. <i>Scientific Reports</i> , 2017, 7, 8894.	3.3	13
87	Do we need to target "prediabetic" hypertensive patients?. <i>Journal of Hypertension</i> , 2005, 23, 2119-2125.	0.5	12
88	Antihypertensive therapy in patients with metabolic syndrome. <i>Current Opinion in Nephrology and Hypertension</i> , 2006, 15, 493-497.	2.0	12
89	What Do Spanish Physicians Believe and Expect about Telemedicine? Results of a Delphi-Based Survey. <i>Telemedicine Journal and E-Health</i> , 2008, 14, 42-48.	2.8	12
90	How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?. <i>Journal of Hypertension</i> , 2010, 28, 1595-1598.	0.5	12

#	ARTICLE	IF	CITATIONS
91	Frequency and Prognosis of Treated Hypertensive Patients According to Prior and New Blood Pressure Goals. <i>Hypertension</i> , 2019, 74, 130-136.	2.7	12
92	Should Hypertension Guidelines Be Changed for Hypertensive Patients With the Metabolic Syndrome?. <i>Journal of Clinical Hypertension</i> , 2007, 9, 595-600.	2.0	11
93	Should diuretics always be included as initial antihypertensive management in early-stage CKD?. <i>Current Opinion in Nephrology and Hypertension</i> , 2009, 18, 392-396.	2.0	11
94	Heart rate and heart rate variability in resistant versus controlled hypertension and in true versus white-coat resistance. <i>Journal of Human Hypertension</i> , 2014, 28, 416-420.	2.2	11
95	Ambulatory Blood Pressures in Hypertensive Patients Treated With One Antihypertensive Agent: Differences Among Drug Classes and Among Drugs Belonging to the Same Class. <i>Journal of Clinical Hypertension</i> , 2015, 17, 857-865.	2.0	11
96	Minor abnormalities of renal function: a situation requiring integrated management of cardiovascular risk. <i>Fundamental and Clinical Pharmacology</i> , 2005, 19, 429-437.	1.9	10
97	Predictors of the Evolution of Microalbuminuria. <i>Hypertension</i> , 2006, 48, 832-833.	2.7	10
98	New clinical concepts after the ONTARGET trial. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 685-689.	1.5	10
99	Association of clinic and ambulatory heart rate parameters with mortality in hypertension. <i>Journal of Hypertension</i> , 2020, 38, 2416-2426.	0.5	10
100	Antihypertensive therapy and short-term blood pressure variability. <i>Journal of Hypertension</i> , 2021, 39, 349-355.	0.5	10
101	Tolerability of High Doses of Lercanidipine versus High Doses of Other Dihydropyridines in Daily Clinical Practice: The TOLERANCE Study. <i>Cardiovascular Drug Reviews</i> , 2008, 26, 2-9.	4.1	9
102	A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients. <i>Blood Pressure</i> , 2011, 20, 322-334.	1.5	9
103	Isolated clinic hypertension: diagnostic criteria based on 24-h blood pressure definition. <i>Journal of Hypertension</i> , 2010, 28, 2407-2413.	0.5	9
104	Antiproteinuric effect of angiotensin-converting enzyme inhibition and C5b-9 urinary excretion in membranous glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 1997, 12, 2576-2579.	0.7	8
105	Mycophenolate mofetil slows the decline of renal function in patients with biopsy-proven chronic rejection: a collaborative pilot study. <i>Transplantation Proceedings</i> , 1999, 31, 2267-2269.	0.6	8
106	Usefulness of ambulatory blood pressure monitoring (ABPM) in daily clinical practice: Data from the Spanish ABPM registry. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014, 41, 30-36.	1.9	8
107	Asociación entre disminución de la función renal y actividad metaloproteínasa-9 en el paciente hipertenso. <i>Nefrología</i> , 2019, 39, 184-191.	0.4	8
108	Los riñones también hablan español. <i>Nefrología</i> , 2021, 41, 225-226.	0.4	8

#	ARTICLE	IF	CITATIONS
109	2021 Spanish Society of Hypertension position statement about telemedicine. <i>Hipertension Y Riesgo Vascular</i> , 2021, 38, 186-196.	0.6	8
110	Comparative Study of Home and Office Blood Pressure in Hypertensive Patients Treated with Enalapril/HCTZ 20/6 mg: The ESPADA Study. <i>Blood Pressure</i> , 2000, 9, 355-362.	1.5	7
111	Clinical trials in nephrology: success or failure. <i>Current Opinion in Nephrology and Hypertension</i> , 2007, 16, 59-63.	2.0	7
112	Early renal and vascular damage within the normoalbuminuria condition. <i>Journal of Hypertension</i> , 2021, 39, 2220-2231.	0.5	7
113	The Importance of Integrated Risk Management When Treating Patients with Hypertension: Benefits of Angiotensin II Receptor Antagonist Therapy. <i>Clinical and Experimental Hypertension</i> , 2008, 30, 397-414.	1.3	6
114	A review of the benefits of early treatment initiation with single-pill combinations of telmisartan with amlodipine or hydrochlorothiazide. <i>Vascular Health and Risk Management</i> , 2013, 9, 521.	2.3	6
115	Association between renal dysfunction and metalloproteinase (MMP)-9 activity in hypertensive patients. <i>Nefrologia</i> , 2019, 39, 184-191.	0.4	6
116	TCA Cycle and Fatty Acids Oxidation Reflect Early Cardiorenal Damage in Normoalbuminuric Subjects with Controlled Hypertension. <i>Antioxidants</i> , 2021, 10, 1100.	5.1	6
117	Urine Haptoglobin and Haptoglobin-Related Protein Predict Response to Spironolactone in Patients With Resistant Hypertension. <i>Hypertension</i> , 2019, 73, 794-802.	2.7	6
118	Renal protection by antihypertensive therapy. <i>Current Hypertension Reports</i> , 2002, 4, 324-328.	3.5	5
119	Review: ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003, 4, 74-79.	1.7	5
120	Renal and cardiovascular events: do they deserve the same consideration in clinical trials?. <i>Journal of Hypertension</i> , 2009, 27, 1743-1745.	0.5	5
121	Detection and Treatment of Resistant Hypertension. <i>Current Hypertension Reports</i> , 2010, 12, 325-330.	3.5	5
122	TRENDS IN ALBUMINURIA UNDER RENIN-ANGIOTENSIN SYSTEM SUPPRESSION: HT.3.05. <i>Journal of Hypertension</i> , 2010, 28, e446-e447.	0.5	5
123	Guía de actuación para el farmacéutico comunitario en pacientes con hipertensión arterial y riesgo		



#	ARTICLE	IF	CITATIONS
127	Hope in Life and Value of blood pressure control. Journal of Hypertension, 2004, 22, 2265-2266.	0.5	4
128	Prediabetes and cardiovascular risk in hypertensive patients. Current Hypertension Reports, 2006, 8, 97-100.	3.5	4
129	Kidney protection: a key target in the management of patients with diabetes. Journal of Hypertension, 2009, 27, S15-S18.	0.5	4
130	Hipertensi3n arterial nocturna. Hipertension Y Riesgo Vascular, 2010, 27, 26-33.	0.6	4
131	Antihypertensive drug use in resistant and nonresistant hypertension and in controlled and uncontrolled resistant hypertension. Journal of Hypertension, 2018, 36, 1563-1570.	0.5	4
132	How do ultrafine particles in urban air affect ambulatory blood pressure?. Journal of Hypertension, 2020, 38, 845-849.	0.5	4
133	Los ri3ones tambi3n hablan espa3ol: iniciativas hacia la estandarizaci3n de nuestra nomenclatura nefrol3gica. Nefrologia, 2022, 42, 223-232.	0.4	4
134	A Prospective Comparison of Four Antihypertensive Agents in Daily Clinical Practice. Journal of Clinical Hypertension, 2001, 3, 139-144.	2.0	3
135	Cerebrovascular protection and antihypertensive therapy. Current Opinion in Nephrology and Hypertension, 2004, 13, 507-512.	2.0	3
136	Are differences in calcium antagonists relevant across all stages of nephropathy or only proteinuric nephropathy?. Current Opinion in Nephrology and Hypertension, 2007, 16, 422-426.	2.0	3
137	New guidelines of the European society of hypertension. Current Hypertension Reports, 2008, 10, 337-338.	3.5	3
138	Hyperkalemia Risk and Treatment of Heart Failure. Heart Failure Clinics, 2008, 4, 455-464.	2.1	3
139	Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial. Lancet, The, 2009, 374, 26.	13.7	3
140	ARBs and ACEIs together in the treatment of hypertension and its complications? current practical recommendations. Expert Opinion on Pharmacotherapy, 2010, 11, 2619-2623.	1.8	3
141	Office and ambulatory blood pressure control in hypertensive patients treated with different two-drug and three-drug combinations. Clinical and Experimental Hypertension, 2016, 38, 409-414.	1.3	3
142	Denervaci3n renal para el tratamiento de la hipertensi3n arterial resistente en Espa3a. Registro Flex-Spyral. Revista Espanola De Cardiologia, 2020, 73, 615-622.	1.2	3
143	Differential metabolic profile associated with the condition of normoalbuminuria in the hypertensive population. Nefrologia, 2020, 40, 439-445.	0.4	3
144	Prevalence of office and ambulatory hypotension in treated hypertensive patients with coronary disease. Hypertension Research, 2020, 43, 696-704.	2.7	3

#	ARTICLE	IF	CITATIONS
145	Prognostic Relevance of Short-Term Blood Pressure Variability. Hypertension, 2020, , HYPERTENSIONAHA11914508.	2.7	3
146	Variations in Circulating Active MMP-9 Levels during Renal Replacement Therapy. Biomolecules, 2020, 10, 505.	4.0	3
147	The kidney in heart failure: role of angiotensin II. Current Opinion in Nephrology and Hypertension, 1999, 8, 153-156.	2.0	3
148	Role of ambulatory blood pressure on prediction of cardiovascular disease. A cohort study. Journal of Human Hypertension, 2023, 37, 279-285.	2.2	3
149	Renal participation in cardiovascular risk in essential hypertension. Expert Review of Cardiovascular Therapy, 2003, 1, 309-315.	1.5	2
150	Advantages of new cardiovascular risk-assessment strategies in high-risk patients with hypertension. Clinical Therapeutics, 2005, 27, 1658-1668.	2.5	2
151	Renal protection in diabetic patients: benefits of a first-line combination of perindopril and indapamide (Preterax®). Journal of Hypertension, 2006, 24, S9-S12.	0.5	2
152	Blood pressure lowering or selection of antihypertensive agent: which is more important?. Nephrology Dialysis Transplantation, 2006, 21, 843-845.	0.7	2
153	Factores y causas de mal control y estrategias de corresponsabilidad médico-paciente en el control de la hipertensión. Resultados de los estudios COROPINA y COREVALUA del programa CORRESPONDE. Hipertension, 2007, 24, 93-100.	0.0	2
154	Papel del personal de enfermería en el control de la hipertensión arterial y en la investigación cardiovascular. Hipertension Y Riesgo Vascular, 2010, 27, 41-52.	0.6	2
155	Reflections on two consensus documents about chronic kidney disease. Nefrología, 2015, 35, 127-130.	0.4	2
156	Modification over time of pulse wave velocity parallel to changes in aortic BP, as well as in 24-h ambulatory brachial BP. Journal of Human Hypertension, 2016, 30, 186-190.	2.2	2
157	Renal denervation for the treatment of resistant hypertension in Spain. The Flex-Spyral Registry. Revista Espanola De Cardiologia (English Ed ), 2020, 73, 615-622.	0.6	2
158	Perfil metabólico diferenciador asociado a la condición de normoalbuminuria en la población hipertensa. Nefrología, 2020, 40, 440-445.	0.4	2
159	Chronic kidney disease and global cardiovascular risk in essential hypertension. Minerva Medica, 2004, 95, 375-83.	0.9	2
160	Evidencias generadas por el proyecto CARDIORISC. Hipertension Y Riesgo Vascular, 2010, 27, 4-8.	0.6	1
161	Response to Bedtime Hypertension Treatment Increases Ambulatory Blood Pressure Control and Reduces Cardiovascular Risk in Resistant Hypertension. Hypertension, 2011, 58, .	2.7	1
162	Management of Resistant Hypertension in a Multidisciplinary Unit of Renal Denervation: Protocol and Results. Revista Espanola De Cardiologia (English Ed ), 2013, 66, 364-370.	0.6	1

#	ARTICLE	IF	CITATIONS
163	Long-term blockade of the renin-angiotensin system: an adequate evaluation is still needed. <i>Hypertension Research</i> , 2014, 37, 701-702.	2.7	1
164	Contribution of the ABP-International study to the definition of night-time tachycardia. <i>Journal of Hypertension</i> , 2014, 32, 2101.	0.5	1
165	Second denervation in a patient with resistant hypertension. <i>Clinical Research in Cardiology</i> , 2016, 105, 880-883.	3.3	1
166	Progression of Renal Insufficiency in Patients with Essential Hypertension Treated with Renin Angiotensin Aldosterone System Blockers: An Electrocardiographic Correlation. <i>Diseases (Basel)</i> , 2016, 10, 50-60.	0.0	0
167	Influence of Chronic Kidney Disease Development and Renin-angiotensin System Inhibition on Cardiovascular Prognosis. <i>Current Medicinal Chemistry Cardiovascular and Hematological Agents</i> , 2005, 3, 55-60.	1.7	1
168	Cardiovascular therapy in patients with renal insufficiency. <i>Cardiovascular Drugs and Therapy</i> , 2002, 16, 497-501.	2.6	0
169	Development of chronic kidney disease in essential hypertension during long-term therapy. <i>Current Opinion in Nephrology and Hypertension</i> , 2004, 13, 495-500.	2.0	0
170	An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1587-1596.	1.8	0
171	Treatment of High-Risk Hypertensive Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2006, 13, 13-19.	2.2	0
172	Main Issues for Achieving Blood Pressure Goals. <i>Journal of Clinical Hypertension</i> , 2006, 8, 766-767.	2.0	0
173	Office vs. ambulatory control of hypertension in CHD patients. <i>International Journal of Cardiology</i> , 2010, 145, 352.	1.7	0
174	Presión arterial medida en la consulta y presión arterial real. ¿Son similares?. <i>Hipertension Y Riesgo Vascular</i> , 2012, 29, 29-30.	0.6	0
175	Abordaje de la diabetes mellitus tipo 2 a través del cotransportador sodio-glucosa tipo 2: ¿tiene sentido?. <i>Medicina Clínica</i> , 2016, 147, 22-25.	0.6	0
176	Patient with White-Coat Hypertension. <i>Practical Case Studies in Hypertension Management</i> , 2019, , 1-10.	0.0	0
177	Patient with Masked Hypertension. <i>Practical Case Studies in Hypertension Management</i> , 2019, , 11-21.	0.0	0
178	Patient with Isolated Diurnal Hypertension. <i>Practical Case Studies in Hypertension Management</i> , 2019, , 23-32.	0.0	0
179	Patient with Isolated Nocturnal Hypertension. <i>Practical Case Studies in Hypertension Management</i> , 2019, , 33-42.	0.0	0
180	Patient with Resistant Hypertension. <i>Practical Case Studies in Hypertension Management</i> , 2019, , 53-65.	0.0	0

#	ARTICLE	IF	CITATIONS
181	Patient with Drug-Induced Hypotension. Practical Case Studies in Hypertension Management, 2019, , 75-84.	0.0	0
182	Hypertension and 24-hour Ambulatory Blood Pressure Monitoring. Practical Case Studies in Hypertension Management, 2019, , .	0.0	0
183	Prediction of the early response to spironolactone in resistant hypertension by the combination of matrix metalloproteinase-9 activity and arterial stiffness parameters. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, , .	3.0	0
184	P1024INFLUENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN THE EVOLUTION OF RENAL FUNCTION IN DIABETIC PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
185	Hyperkalemia Risk and Treatment of Heart Failure. , 2012, , 81-99.		0
186	Hyperkalemia Risk and Treatment of Heart Failure. , 2012, , 23-41.		0